RecruitingPhase 2NCT07104812

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)


Sponsor

Mayo Clinic

Enrollment

15 participants

Start Date

Jan 14, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a low dose of osilodrostat — a drug that blocks excess cortisol production — can help people with mild autonomous cortisol secretion (MACS), a condition where small benign adrenal growths produce slightly too much of the stress hormone cortisol. **You may be eligible if...** - You are 18 or older - You have been diagnosed with MACS based on adrenal imaging and abnormal cortisol suppression tests - You have at least one related health problem such as obesity, high blood pressure, high blood sugar, high cholesterol, or weak bones **You may NOT be eligible if...** - You have adrenal cancer or suspected malignancy - You have other causes of high cortisol (such as Cushing's syndrome from another source) - You have liver problems or are taking medications that strongly interact with osilodrostat - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOsilodrostat 1 MG

Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks


Locations(1)

Mayo Clinic

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07104812


Related Trials